Healio

Combination bupivacaine, meloxicam may reduce pain, opioid use after TKA

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — Results showed use of Zynrelef as part of a multimodal analgesia protocol may significantly ...
Monthly Prescribing Reference

Novel Meloxicam Formulation Reduces Postop Pain in Two Trials

A reduction in opioid usage over the entire treatment period was observed in patients treated with MR-107A-02 vs placebo. Topline data were announced from two phase 3 studies evaluating MR-107A-02 for ...
Business Wire

Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies

SAN DIEGO--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on developing novel best-in-class treatment solutions to address some of the ...
Seeking Alpha

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain ...
Medscape

Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug

Meloxicam is an enolcarboxamide with preferential COX-2 inhibitory activity. In vitro studies with human tissues have confirmed the high affinity of meloxicam for COX-2, whereas COX-1 was inhibited ...